Contingency Management for Opioid Use Disorder in Inpatients at Assiut University Hospital

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

55 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-01

Study Completion Date

2027-02-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A scientific study to design and implement a contingency management (CM) program, and to evaluate its effectiveness in promoting abstinence and treatment adherence among individuals with opioid use disorder, as well as to explore its potential for broader implementation in clinical settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Contingency Management to Improve Medication for Opioid Use Disorder Continuation After the Emergency Department

NCT07129902

Opioid Use Disorder

NOT_YET_RECRUITING NA

Contingency Management to Enhance Office-Based Buprenorphine Treatment

NCT04024059

Opioid-use Disorder

COMPLETED NA

Contingency Management for Opioid and Stimulant Use Disorders in Primary Care

NCT05288751

Opioid Use Disorder Stimulant Use Disorder

ACTIVE_NOT_RECRUITING NA

Reentry Incentives and Support for Engagement With Contingency Management

NCT07322588

Opioid Use Disorder

NOT_YET_RECRUITING NA

Incentives to Decrease Opioid Use - Pilot

NCT04235582

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Addiction and drug use can have negative consequences on the health, economy, productivity, and social aspects of communities. Addictive disorders are of high prevalence and often associated with other psychiatric and somatic diseases. Severe cases, often complicated by multiple dependencies of substances and advanced stages of the disease can require the involvement of a variety of caregivers, who are requested to sufficiently cooperate and interact to guarantee an optimal outcome of treatment. Tolerance and withdrawal are the two hallmark criteria of physiological addiction, and, arguably, may also be considered as aspects of a more general concept of preoccupation (or as features that contribute to preoccupation). Tolerance refers to the need to engage in the behavior at a relatively greater level than in the past to achieve previous levels of appetitive effects. As tolerance increases, one likely spends more time locating and engaging in an addiction. Thus, tolerance may indicate increasing preoccupation. Withdrawal refers to physiological or acquired discomfort experienced upon abrupt termination of an addictive behavior. If withdrawal symptoms exist, and worsen, one is likely to be spending more and more time recovering from the after-effects of the addiction, and focused in thought and action on how to cope (e.g., by using again). That is, one is more preoccupied with the addiction when one is spending more time locating, engaging, and recovering from that behavior, and this may reflect processes of tolerance and withdrawal. Historically, addiction treatment systems and research have been organized to provide and improve the outcomes of acute episodes of care. The conceptual model has been that an addicted person seeks treatment, completes an assessment, receives treatment, and is discharged, all in a period of weeks or months. This orientation stands at variance with clinical experience and studies conducted over several decades, which confirm that, although some individuals can be successfully treated within an acute care framework, more than half the patients entering publicly funded addiction programs require multiple episodes of treatment over several years to achieve and sustain recovery. The progress of many patients is marked by cycles of recovery, relapse, and repeated treatments, often spanning many years before eventuating in stable recovery, permanent disability, or death.

Contingency management (CM) is a promising intervention for treating drug dependence. CM treatments rearrange the environment to detect drug use readily and to promote participation in activities that are inconsistent with drug use. These treatments encourage participation upon objective evidence of drug abstinence or engagement in non-drug-related activities. Contingency management (CM) is a behavioral intervention where reinforcement is provided when biologically confirmed drug abstinence is demonstrated, typically in the form of a urine test. Unlike some substance use disorders (SUDs) where there are pharmacological treatments available, all empirically supported treatments for stimulant use disorder are behavioral, and contingency management (CM) has the strongest support. CM, or the provision of reinforcement to encourage abstinence from substances or other behaviors, has strong empirical support, established over decades of research, for the treatment of SUDs, including stimulant, nicotine, alcohol, and opioid use disorders. Although CM is efficacious, it is rarely implemented in practice. A primary obstacle is cost.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid Use Disorder (OUD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Contingency Management Intervention

Group Type EXPERIMENTAL

contingency management

Intervention Type BEHAVIORAL

Participants with opioid use disorder admitted to the inpatient addiction management unit will receive a contingency management (CM) program as a behavioral intervention. The program consists of providing positive reinforcement (small rewards or incentives) contingent upon objective evidence of desired behaviors, primarily drug abstinence verified by urine toxicology screening. The intervention will be delivered throughout the inpatient stay (approximately two weeks). Participants' adherence and abstinence will be monitored, and rewards will be adjusted based on performance.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

contingency management

Participants with opioid use disorder admitted to the inpatient addiction management unit will receive a contingency management (CM) program as a behavioral intervention. The program consists of providing positive reinforcement (small rewards or incentives) contingent upon objective evidence of desired behaviors, primarily drug abstinence verified by urine toxicology screening. The intervention will be delivered throughout the inpatient stay (approximately two weeks). Participants' adherence and abstinence will be monitored, and rewards will be adjusted based on performance.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be 18 years of age or older
* Have a diagnosis of a substance use disorder (SUD) according to DSM-5 criteria
* Be able to understand and provide informed consent
* Be willing to comply with study procedures, including regular drug screening and attendance tracking
* Must be able to swallow tablets

Exclusion Criteria

* Have a severe cognitive impairment or active psychosis that interferes with participation
* Currently experiencing a medical condition that would make participation unsafe

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No